APA (7th ed.) Citation

Plummer, R., Cook, N., Arkenau, T., Melear, J., Redfern, C., Spira, A. I., . . . Wesolowski, R. (2018). 1437PPhase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy292.059

Chicago Style (17th ed.) Citation

Plummer, R., et al. "1437PPhase I Dose Expansion Data for M6620 (formerly VX-970), a First-in-class ATR Inhibitor, Combined with Gemcitabine (Gem) in Patients (pts) with Advanced Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy292.059.

MLA (9th ed.) Citation

Plummer, R., et al. "1437PPhase I Dose Expansion Data for M6620 (formerly VX-970), a First-in-class ATR Inhibitor, Combined with Gemcitabine (Gem) in Patients (pts) with Advanced Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy292.059.